FDA Approves Takeda's Orzeyful for Narcolepsy Type 1, Marking a Shift in Treatment Paradigm
First-in-Class Treatment Targeting the Underlying Mechanism
The U.S. Food and Drug Administration (FDA) approved Orzeyful (orexpretant) from Takeda Pharmaceutical (TAK) in August 2026 for the treatment of adult narcolepsy type 1 (NT1). This oral medication selectively activates orexin receptor 2 (OX2R), restoring the orexin signaling that is deficient in the disease. This represents a shift in the treatment paradigm, moving away from treatments that individually address symptoms like excessive daytime sleepiness or cataplexy, and towards a treatment that addresses both daytime and nighttime symptoms through a single mechanism.
Approval Based on Two Phase 3 Clinical Trials
The approval is based on the FirstLight and RadiantLight Phase 3 clinical trials, which were conducted in 19 countries. FirstLight enrolled 168 patients who were randomized to receive orexpretant 1 mg or 2 mg twice daily, or placebo. RadiantLight enrolled 105 patients who were randomized to receive 2 mg twice daily or placebo. In both trials, all doses of orexpretant achieved statistically significant improvements compared to placebo in the Maintenance of Wakefulness Test (MWT) at week 12, the Epworth Sleepiness Scale (ESS), and the frequency of cataplexy attacks, with p-values less than 0.001. The most common adverse events were insomnia, nocturia, and urinary frequency, and no serious adverse events related to treatment were observed.
Differentiation from Existing Standard of Care
The current competitive landscape includes Xywav (calcium, magnesium, potassium, and sodium oxybate) and Xyrem (sodium oxybate) from Jazz Pharmaceuticals (JAZZ), Lumryz (extended-release sodium oxybate) from Avadel Pharmaceuticals (AVDL), Sunosi (solriamfetol) and Wakix (pitolisant) from Axsome Therapeutics (AXSM). Oxybates treat cataplexy and excessive daytime sleepiness but are associated with central nervous system depression and limited distribution, while wake-promoting agents do not address the underlying orexin deficiency. Orzeyful differentiates itself through its OX2R-targeted mechanism and its potential to improve both daytime and nighttime symptoms. However, the actual rate of adoption will depend on reimbursement criteria and long-term safety data.
Commercial and Regulatory Expansion
There are approximately 180,000 patients with narcolepsy in the United States, most of whom have NT1, but many are undiagnosed. Xywav, a market-proven product, generated net sales of USD 1.7 billion in 2025, demonstrating commercial demand. Orzeyful was first approved by the National Medical Products Administration (NMPA) in China on July 22, 2026, for the treatment of NT1 in patients aged 16 years and older, and is currently under review in Japan following its designation as a Sakigake product. The U.S. launch will occur after the FDA approval and completion of the Drug Enforcement Administration (DEA) scheduling process. This approval represents a regulatory success for Takeda's internally developed asset, rather than a licensed product.
With FDA approval, Orzeyful becomes the first-in-class OX2R selective agonist, validated in Phase 3 trials (FirstLight, 168 patients; RadiantLight, 105 patients), and enters the U.S. NT1 market. In the short term, it will create competition and pricing pressure for Jazz Pharmaceuticals (JAZZ), which holds Xywav with USD 1.7 billion in 2025 sales, and Avadel Pharmaceuticals (AVDL), which has Lumryz, a once-daily oxybate. From an R&D perspective, despite the discontinuation of TAK-994 due to hepatotoxicity, it demonstrates the clinical and regulatory validity of the orexin agonist class, raising the bar for valuation of subsequent OX2R pipelines. Long-term success will depend on identifying and treating NT1 patients, reducing the use of existing combination therapies, and demonstrating long-term hepatic and urinary safety.